|
Real world outcomes for maintenance avelumab treatment in locally advanced/metastatic urothelial cancer after platinum-based chemotherapy. |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Bayer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Bristol Myers Squibb Foundation; Ipsen |
Research Funding - Bristol Myers Squibb Foundation (Inst) |
Travel, Accommodations, Expenses - Ipsen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbott Laboratories |
Consulting or Advisory Role - AstraZeneca/MedImmune; Ferring; Janssen; Roche |
Speakers' Bureau - AstraZeneca/MedImmune; MSD Oncology; Nucleix; Roche |
Research Funding - Roche/Genentech |
Travel, Accommodations, Expenses - European Association of Urology |
|
|
Honoraria - Merck; Pfizer |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Merck; Pfizer; Roche |
Research Funding - Boehringer Ingelheim; Janssen-Cilag; Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Janssen-Cilag; MSD Oncology; Pfizer; Pierre Fabre; Roche |